Clinical Cascade

PEPFAR

4th Annual USAID Global Health Local Partner Meeting Presenters: Thomas Minior, USAID/HQ Meena Srivastava, USAID/HQ Kristina Bishop, USAID/HQ Patrick Hazelton, USAID/HQ



Clinical Cascade

Adult Care and Treatment PMTCT Pediatric & Adolescent Testing, Care and Treatment HIV Testing Key Populations





2

Adult Care & Treatment

Presenter: Thomas Minior Adult Clinical Branch Chief, Prevention Care & Treatment Division, GH/OHA





3

Good News......

- While COVID did interrupt a lot of health service provision globally, USAID-supported HIV treatment programs were remarkably resilient.
 - TX_CURR increased 12% since FY20.
 - IIT has fallen to 2.5% in FY22Q3
 - Viral suppression reached **94.7%** by FY22Q3
- This continued progress highlights the good work you have all done in extremely challenging conditions.
- As such, there are <u>not</u> a lot of substantive changes upcoming in clinical service delivery in COP23 – focus on refinements, reaching gaps in priority populations, etc.


"Do What We Do.. Just More. And Better"

& New Opportunities.....



"Re-Imagining PEPFAR":

- PEPFAR **is** entering a new phase.
- As many of our programs mature and get close (or even surpass) 95-95-95 targets, there's a greater focus on ensuring longterm sustainability while reaching remaining programmatic gaps, as outlined in Amb. Nkengasong's "<u>Reimagining</u> <u>PEPFAR's Strategic Direction</u>"
- While not ubiquitous, technology allows us to communicate with our clients and monitor progress – we can better "<u>individualize</u>" care.





Advancing Advanced Disease

- PHIA surveys demonstrate that 15.4% (range 7-21%) of persons testing positive (but self-reported HIV negative) had a CD4 <200 cells/mm3.
- PEPFAR started re-investing in Advanced HIV Disease (AHD) in COP22 → still limited scale.
- Step 1: CD4 testing for all new clients, those out of care >1 year, and those with documented virologic failure.
- Package of services for those with AHD:
 - Immediate ART
 - Cotrimoxazole (prevents PCP, Toxo)
 - TB Screening & Treatment (half of AHD mortality)
 - CrAg screening & treatment
 - Nutitional assessment and supplementation for SAM
- Consider supplementing with periodic "death audits" can better understand quality of care & patterns of mortality

Advancing Advanced Disease = Also advancing TB/HIV..

% TPT Completion	% of <i>i</i>	% of ART Patients Screened for TB		% TB Screen Positive		% specimens sent via GeneXpert, of total test types			
85%		77%		2.0%		82%			
		6,927,974			USAID Partner progress, TE			3 Cascade, FY22Q2	
	5,260,847		5,367,946						
520,789 614,409 PT Completion TPT Initiation	on Negative TB Screening	ART Patients	TB Screening	107,099 Positive TB Screening	80,670 Specimen Sent	92,717 Specimen Sent Xpert	16,663 Specimen Returned Positive	30,024 TB Treatment Initiation	
Screen Negative for TB and TP Preventive Therapy (TPT)			Screen Positive for TB and TB Treatment						

*Crossdata analysis done by the TB division on TBHIV missed cases and mortality


- Roughly, 4 ART patients die for every 5 we put in TB treatment*
- Overall, we've been making progress on both TPT coverage & completion.
 - Need to keep making progress and integrate newer, shorter regimens (3HP) where feasible.
- The TB screening positivity yield remains low at 2% (should be over 5%), we need to improve TB screening, dedicating more time to do it correctly and/or use better WHO recommended screening tools
- Also on improving access to molecular testing (GeneXpert), but room to grow. If you support sites still doing smears, ask why...

Some more progress & emphasis is needed in two areas in particular:


- TB Case finding (annual ~200K estimated TB/HIV missed cases in Pepfar*): Integrating CAD (Computer-aided detection) radiography, Urine TB-LAM and (of course) molecuar testing (WMRD, like GeneXpert, Truenet,etc)
- Improved TB contact investigation amog ART contacts
- Improved quality of TPT adherence and completion

Cervical Cancer: OMG, are LPM IPs ready for HPV?

- In 2021, WHO released updated guidelines recommending an additional step in the cervical cancer approach: "Screen, Triage, Treat"
- PEPFAR seeking to do a phased approach to ensure:
 - Effective (>90%) linkage to treatment for those with positive lesions
 - Optimizing lab infrastructure to ensure rapid (7 day) Turn-Around Time for HPV testing
 - SOPs for quality assurance of VIA
 - Systems for providing results and tracking clients through the cascade




Better Service Integration for Clients




- Amb. Nkengasong has highlighted service integration under his Priority Pillar #3, placing particular emphasis on NCD (non-communicable disease) and Mental Health
- Siloed HIV programming misses opportunities (such as noncommunicable disease (NCD) treatment) to reduce morbidity and mortality for PLHIV.
 - Clients have other health needs; fractured care impedes continued adherence & suppression...
 - Less verticalized programming can encourage sustainability
- However, there are risks of service quality suffering → need to take a thoughtful approach, tailored to the local epidemic and health system, listening to PLHIV communities and ministries of health.





Optimizing DSD – Assessing Patient Preference




- We've made substantial progress shepherding MMD and DSD models
- Life circumstances change: Important to assess periodically
- Complement with • periodic qualitative assessments and behavioral nudges

Uganda Patient-Preference Pilot 2022 courtesy of USAID/Uganda

Fundi-tunity..

Don't Forget about non-pregnant WLHIV



OU: GLOBAL |Period: FY22 Q2 | Agency: All | Partner/IM:All | SNU:All | PSNU:All | Sex: All | Age:All Source: Treatment Workbook, MSD FY22 Q3i, Last Update: 9/21/2022 10:21:49 PM

- There were 100,00 interruptions in treatment for women just in the 30-39 year old demographic
- Most of our services for women center around pregnancy
 - <u>Qualitative opportunity</u>: what are the barriers nonpregnant and older women face and how can we overcome them?</u>
- Services that produce even small percentage reductions in IIT can make a huge impact on the program

Fundamenta

resistance

World Heat

Rhee et al JAC 2019

Bringing it back to the basics: TLD! (Rah rah!)

- Occasionally, people will fail DTG-based regimens \rightarrow but it's almost never due to resistance!
- Global Treatment Guidance is likely to change • in coming years away from sequential 1st/2nd line approaches
- For now, though we need to finish the job: ٠
 - Countries/Partners where TLD is <90% of TX CURR
 - pDTG
 - TLD for 2nd Line
- Be sure to monitor weight gain regularly in all • clients, including those on TLD

Prevalence of DTG resistance in ART experienced INSTI-naïve persons** Percentage resistance (95% CI)^a Population Past ART DTG ART (q24h) VF (95% CI) AuthorVr Subjects Weeks DTG + 2 NRTIs (1 NRTI pre- 312 Aboud19 RCT (DAWNING) VF on a 1st-line NNRTI 17.6 (13.7-22.4) 0 (0-1.5) 24 dicted to be fully active) 36.2 (30.9-41.8) 0.6 (0.1-2.3) regimen Cohn13 RCT (SAILING) h/o resistance to ≥2 ARV DTG + OB (1 to 2 ARVs pre-354 48 29.1 (24.4-34.1) 0.6 (0.1-2) closses dicted to be fully active) 48 31.1 (19.9-44.3) 4.9 (1-13.7) Vavro18 trial (P1093) heavily treated DTG + 08 61 odolescents 48 16.7 (12.3-21.9) 0.8 (0.1-2.8) Lepik17 infrequent h/o NRTI resist- DTG + 2 NRTIs 252 ance (<10%) 48 28.0 (18.6-37.5), I²=91 0.7 (0.2-1.2), I²=0 ALL 48 979 weeks "Prevalence among all on treatment (meta-analysis as of January 2019 lients on ART may fail sins load 50 coeles/mL or treatment discontinuation fr ary reason. For the cobort studies, the proportion of but it's almost never DTG persons with VF alter the median time of follow-up was provide

Prevalence of DTG resistance in triple ART clinical studies World Health

* Percentage of those receiving DTG ART developing an INSTI resistance mutation

Pooled proportions and 95% Ci of VF and VF with INSTI resistance estimated using a random-effects meta-regression

Study	Рор	ART	Weeks	DTG, N	VL >50cps/ml ITT, n, (%)	Incident DTG res in PDVF (n/N (%)	
ARIA	ART naive	DIG(ABC)3TC	48	250	45 (18.0)	0/6 (0)	
FLAMINGO		DTG+ (TDF/FTC or ABC/3TC)	96	242	48 (19.8)	0/2 (0)	
CS 1489		DTG+ABC+3TC	144	315	50 (15.9)	0/6 (0)	
GS 1490		DTG+FTC+TAF	144	325	52 (16.0)	0/7 (0)	
SINGLE		DIG+AHC+31C	144	414	118 (28.5)	0(11(0)	
SPRING-2		DTG+(TDF/FTC or ABC/3TC)	96	411	71 (17.6)	0/1 (0)	
NAMSAL		DTG+TDF+FTG	96	310	81 (26.0)	0/8 (0)	
ADVANCE		DTG+ (TDE/FTC or TAE/FTC	96	702	151 (21.5)	0/118 (0)	
INSPIRING		DTG +2 NRTIS	48	69	17 (24 6)	0.2 (0)	
DuLPHIN-2		DTG +TDF+FTC/3TC	72	125	9 (7.2)	0/3 (0)	
Semini 1 & 2		D1G + 10+4-1G	144	/1/	114(15.9)	0/9 (0)	
Oddsey A***		DTG +2 NRTIs	96	151	37 (24.0)	0/15 (0)	
P1093***	ART experience INSTI	DTG+08	192	142	15 (65.2)	8/36 (22.2)	
EMEDT	nave	DTG+TDF+3TC	24	1893	36 (2.0)	2/5 (40.0)	
Oddsory B***		DTG +2 NRTIs	96	198	43 (21.9)	4/32 (12.5)	
SAILING		DTG+0B	360	357		7/46 (15.2)	
NADA		DTG+2 NTRIs	96	235	46 (19.6)	//20 (35.0)	
ARTIST		DTO+TDF+3TC	24	60	9 (15.0)	0/1 (0)	
DAWNING		DTG+2 NRTIs	158	324		7/16 (43.8)	

Slides from WHO TWG Meeting 2021

Fundamental

Bringing it back to the basics: Improving VLC

FY22 SUMMARY TABLE					
Percent of TX_CURR on MMD at least 3m ^{1*}	Percent of TX_CURR on MMD 6m ¹ *				
83% (4,054,864/4,901,370)	38% (1,877,745/4,901,370)				
Viral Load Coverage ² Meh	Viral Suppression ¹				
73.2% 72.1% 73.9% (4,813,702)/(6,573,245) (4,819,525)/(6,682,783) (5,031,998)/(6,807,554)	95% (4,769,953/5,031,998)				
Continuity of Treatment ²	Interruptions in Treatment ²				
99% (7,040,232/7,112,872)	2.5% (179,359/7,073,794)				

 We've made strides in reducing IIT, expanding MMD, increasing VL suppression → but VL coverage remains stagnant

Two key points:

- Optimize your VL system (sample delivery routes, result return)
- Take the viral load collection out of the clinic where feasible

OU: GLOBAL | Country: All | Funding Agency: USAID Partner: <Prime Partner (group)> | Mech: All

Source: Executive Dashboard, PSNU x IM Quarterly Hyperfile, Las

And of "Core" se: Don't Forget the Core!

Rapid ART Initiation for all new and returning clients

Proactive support for retention & adherence

Providing management support to improving flow within clinics

Offering a range of service delivery models and drug pickup choices

Optimizing ART regimens (TLD!)

Checking VL annually & rapid result return

U=U Messaging and health literacy

Community-Based Support

Screening for TB and providing appropriate TPT or TB Tx

GBV screening

Instilling a culture of Continuous Quality Improvement

Periodic Data Quality Assessments

Etc..



But of course, with an agency-level VLS rate of 95%, you must be doing all this, so please don't...



Fundamental



In the End, it still boils down to understanding our recipients of care and designing effective & efficient services that empowers them and meets their individual needs.

Reaching mothers, children/adolescents and families

PMTCT and Pediatric & Adolescent Testing, Care and Treatment


Presenter: Meena Srivastava Medical Officer, Pediatric Maternal Clinical Branch, GH/OHA





Global Progress in PMTCT and Reducing New Child Infections

Progress made in PMTCT has stagnated globally, and more effort is needed to close the gaps for mothers and infants




UNAIDS 2022, Improving UNAIDS' paediatric and adolescent estimates UNAIDS Global AIDS Update: In Danger, 2022

Global AIDS Monitoring and UNAIDS 2022 estimates

Source: UNAIDS 2021, 2022


Global Progress Towards Reaching Children Living HIV (CLHIV)

1.7M Children living with HIV in 2021



1. Global AIDS Monitoring and UNAIDS 2022 estimates 2. https://data.unicef.org/resources/hiv-estimates-for-children-dashboard/, 3. https://aidsinfo.unaids.org/ 4. UNAIDS Global AIDS Update: In Danger, 2022


Populations



...and aligns with PEPFAR's AP3 Initiative and UNAIDS Global Alliance

PEPFAR Accelerating Progress in PMTCT and Pediatric HIV (AP3): Objectives

- Reduce new child infections in children <10 years through addressing gaps in the PMTCT program
- Rapid identification, linkage, and treatment of children/adolescents not yet on ART to increase coverage
- 3. Increase rates of pediatric viral load suppression to 95% and reduce mortality




UNAIDS Global Alliance to End AIDS In Children: Objectives

- Early testing and optimized treatment for infants, children, and adolescents living with HIV
- 2. Closing the **treatment gap for pregnant/breastfeeding women** living with HIV and improving continuity of treatment
- **3. Preventing new HIV infections** among pregnant/breastfeeding adolescents and women.
- 4. Addressing rights, gender equality and the social and structural barriers to access services and promote participation

FY22 cumulative (to Q3) USAID PMTCT cascade, global results

Maternal to infant cascade shows gaps in ANC1 testing, EID test by 2 mo of age, and challenges with linking all infants diagnosed with HIV to ART



PMTCT program priorities


Prevent / elminate new child infections through primary prevention, including ANC1 testing, maternal retesting and PrEP for PBFW

Attaining VLS for PBFW through differentiated models, adherence support and U=U


Leveraging OVC/KP platforms to improve CoT / final outcome for mother-infant pairs, especially AGYW



large pool of HIV negative pregnant women in Lesotho in ANC who can be screened for PrEP services




pregnancy/breastfeeding.



Ensuring PBFW access VL testing and attain suppression

Many PBFW are now on TLD, but issues with understanding treatment, adherence support, and stigma remain. Important to ensure VL access through POC where possible, emphasize early ART start, U=U messaging and DSD models





VL access and data Use:

- VLC for PW may be underreported triangulate MER data with program data to improve accuracy.
- Ensuring access to timely VL testing and POC VL (where available)

Supporting Adherence and CoT:

- Supporting PBFW to remain in DSD model of their choice, including MMD
- Providing disclosure support and peer support in the community (e.g. mentor mothers, OVC case managers...)


Early ART and Optimal ARVs:


- Testing and starting WLHIV on ART prior to conception
- Supporting TLD treatment literacy
- Expanding U=U messaging to PBFW
- Enrollment on TLD without prior VL requirement

OVC & KP Programs Supporting Mother-Infant Pairs

OVC and KP programs are uniquely positioned to support continuity of treatment for mother-infant pairs and to ensure the infant's final status is known. OVC activities and interventions should support the unique needs of mothers-infants pairs (priority on AGYW) across all four domains.

۲





- FSW living with HIV and their HEI / children should be assessed and offered enrollment in the OVC program
 - Requires strong coordination with KP, Clinical and OVC programs, parterns and staff

OU Example: Tanzania OVC Program Prioritizing Mother-Infant Pairs

Kizai Kipya (Pact) collaborates with Clinical IPs to identify high volume facilities for HIV-exposed infant (HEI) enrollment:

Enrollment criteria


Enrollment focuses on councils with EID 2mo coverage < 60%.

Priority

- HIV+ positive pregnant adolescent <18y/o
- HIV+ breastfeeding adolescent mothers
- HIV+ positive breastfeeding women

Focusing on

- HIV+ breastfeeding women with late first postnatal care attendance.
- HIV+ breastfeeding women with at least one missed appointment.
- Caregiver of HEI attending PMTCT/RCH site (can be aunt, grandmother etc. who cares for HEI)



FY22Q3 update: 27,265 HEI enrolled in OVC program and 30,141 HIV+ PW reported in FY22 (cumulative, PMTCT_STAT_POS)

Analysis of continuity of care & treatment for mother-baby pairs, EID 2mo coverage, & PMTCT_FO for monitoring of outcomes and impact

HEI Target versus Enrollment

Summary of Key PMTCT Activities

Prevent and identify incident infections

- Maternal retesting at recommended time points; ensure HTS counselor is assigned to MCH
- HIV self-testing for maternal retesting
- Improve M&E for maternal retesting
- PrEP for PBFW
- Link HIV-negative pregnant AGYW to **DREAMS**
- Male partner testing
- Integrate GBV services into ANC/PMTCT

Ensure uptake of ART among PBFW

- Ensure **all ANC facilities** are **testing for HIV** and reporting data accurately
- In countries with low facility attendance, look for case finding opportunities in private facilities and community birth attendance settings
- Engage **faith-based institutions** and other community structures for demand creation
- Intensify **transition to TLD** for PBFW


Continuity in treatment for PBFW

- AGYW-friendly PMTCT services and DSD/MMD, e.g. group ANC models and new mother programs for AGYW, weekend appointments
- Peer-based support, e.g. mentor mothers and peer support groups
- Align OVC support to facilities with high rates of AGYW pregnancies
- QI for VL coverage and suppression in PBFW; improving disaggregated VL data for PBFW

Care and testing for HIVexposed infants

- Improve infant testing uptake and reduce missed tests at all recommended time points, including through community support
- Provide POC EID as part of an optimized lab network
- Track infants until final outcome; e.g. longitudinal cohort monitoring, inclusion in EMRs, continuity coordinators at sites
- OVC support to at-risk HEI and their families

Q3)




FY22 Cumulative Clinical Cascade, Peds (<15 yo) OU: All| PSNU: All | SNU: All

Looking back, Moving forward to identify C/ALHIV

Refocus to strategically find and diagnose C/ALHIV that might have been missed during PMTCT programs - important to optimize a multi-modality approach.

Underachievement on pediatric case-finding (<15yo) in PEPFAR programs




Indicator: HTS_TST_POS | LTS or STAR: All | OU: All | FY: All | Agency: CDC & USAID | Age: Peds

Moving forward to identify C/ALHIV

- 1. Adapting national programs
- 2. Systematically increasing outpatient testing for at-risk children
- 3. Scaling pediatric index testing
- 4. Monitoring testing coverage at all entry points
- 5. Expanding access to HIVST

Index Testing "gap" for children <15y/o, USAID





PEPFAR solutions page:

https://www.pepfarsolutions.org/resources andtools-2/tag/index+testing

Contact your OHA Peds and HTS Advisor if interested in pediatric index testing training

Opportunities to utilize Caregiver / Provider-assisted Oral HIV Screening to identify hard-to-reach biological children while leveraging KP and OVC Programs

Metric # % Offered Index Testing Services (Female 15+ y/o) 19,179 -Offered to Accepted (Female 15+ y/o) 17,182 90% Accepted to Contacts Ratio (Female 15+ y/o to Children 40,482 2.4 <15 y/o) (ratio) Contacts Eligible for Testing (Children <15 y/o) 71% 28,698 Eligible Children <15 v/o Tested 26,952 94% Eligible Children <15 y/o Not Yet Tested 6% 1,746 Index Positivity Children <15 y/o 1,663 6.2% Linkage to ART 1,634 98%

Index testing data from Burundi presented at the International Workshop on HIV & Pediatrics (IWHP 2022, Montreal, abstract <u>here</u>) revealed a gap of 1,746 eligible children not tested because they do not live with parents.

Action: Prioritize and operationalize the introduction of an assisted HIVST screening demonstration in Burundi to address existing pediatric index testing gap.

Supporting the introduction of caregiver and provider-assisted oral HIV screening in <u>children:</u>

- Index testing gap review by OU, IP and geography to characterize biological children we are not reaching with index testing (similar to Burundi example)
- Supply Chain planning, engagement and assessment early on to ensure availability of oral test kits to align with demonstration project
- Follow-up on pricing of Orasure kits by country and where costs are being incurred.
- Country engagement with OHA Peds, HTS, KP, and OVC Advisors


Leaving No Child Behind: Burundi Data

Improve VLC and VLS to ensure C/ALHIV Survive and remain Healthy and Thrive


Ensure that C/ALHIV are prioritized for viral load collection and remain virally suppressed

VLS continues to lag behind globally for children <15yo

Proportion of adults (aged 15+ years) and children (aged 0–14 years) with suppressed viral load among people living with HIV, global, 2015–2020




Consider using pediatric VL blood draw commodities for plasma samples from young children (<5y/o)



Strategies to improve pediatric and adolescent VLC and VLS:

- 1. Complete ART optimization to DTG-based regimens
- 2. Use VL blood draw commodities for children (e.g. butterfly needles)
- 3. Consider decentralization of VL collection to community
- 4. Ensure rapid TAT for VL results and communicate to client
- 5. Scale MMD to all eligible C/ALHIV
- 6. Promote family-centered care and joint appointments
- 7. Increase treatment literacy and promote demand for VL testing
- 8. Utilize POC testing where feasible and practical


Advanced HIV Disease Management for the youngest CLHIV (<5y/o)



Children <15y On ART by FY21Q4 (txcurr by September 21) or TXNEW from Oct21-June 22 (FY22Q3; JUN)


(Tanzania): 82% <5y/o, 70% CLHIV died at home, >50% CLHIV <3 mo on ART, 76% CLHIV with no VL sample

Main causes of death: 42% severe acute malnutrition, 21% TB, 15% stopped, 3% AIDS defining illness




based regimen

Mozambique, Nigeria, and Tanzania account for the highest # of deaths



*among countries with >50 deaths among CLHIV<5 years old in past 4 quarters


Sources: PEPFAR MER Indicator data, ML_death and %ML_death=TX_ML_died/TX_Curr_previous +TX_New current)



Improve VLC and VLS to ensure C/ALHIV are Healthy and Thrive

Ensure that C/ALHIV are prioritized for viral load collection and remain virally suppressed

OU Example: Uganda Service Package Associated with higher Viral Load



Uganda Layered Services Monitored:

- On time Viral Load
- DTG regimen
- IAC initiation
- TPT initiation
- TB Assessment

- MMD

- Appointment kept
- OVC screening assessment
- CHW attachment
- Community visit
- Source: Q3 Audit Data analyzed by USAID/U with IP SITES

OU Best Practice

Leveraging the OVC program to support C/ALHIV and families for improved outcomes and impact

Continue strengthening strategies that support CoT for C/ALHIV and their families, ensure enrollment of the most vulnerable, and monitor 95-95-95 outcomes through the use of custom indicators

Indicators: Tracking progress in Tanzania's OVC program

Number of beneficiaries enrolled in the OVC program by subpopulation

ii. Among CLHIV enrolled in the OVC program

- a. % on ART
- b. % on MMD (3MMD/6MMD)
- c. % with a suppressed viral load
- d. % who reached <=28 days past their expected clinical contact or drug pick-up at the end of the reporting period (ITT)

HELenrolled in the OVC

n. Among	nci entoled in the Ovo program.	Tanzania OVC
a.	2mo EID coverage	
b.	12mo EID coverage	Program
C.	% HIV positive (at any point)	Metrics as
d.	% HIV+ initiated on ART	agreed by
v. Among	Caregivers enrolled in the OVC program	Interagency
a.	% HIV+	team
b.	% of HIV+ on ART	

- c. % on MMD (3MMD/6MMD)
- d. % with a suppressed viral load
- e. % who reached ≥28 days past their expected clinical contact or drug pick-up at the end of the reporting period (IIT)

V. Local ownership and sustainability of the OVC program

- # of OVC beneficiaries supported by economic empowerment activities (e.g., saving & lending groups, income generating activities, vocational training and support) а
- % of OVC portfolio implemented by local partners (USD value and # of children served)
- C. Value (USD) of savings and lending among WORTH/VSLG groups
- d. Approximate value of additional resources leveraged through GOT or private partners
- e. # of CCWs and other social welfare structures supporting OVC

Improving Peds VLS through OVC/Clinical partnerships

OVC Case Workers in Zambia are facilitating VL testing in homes through joint visits with clinical providers through:



·Supported new OVC cadre: Facility-based Case Worker ·Orientation of frontline workers in supported facilities ·Data sharing - (due for VL, no VL result on file, invalid results)

 VL literacy to VCAs Tool tracking VL status of all enrolled VCAs ·Home visits and VL sample collection at convenient times e.g weekends

•Multidisciplinary team visits home (Case Worker + clinical staff)


 Active follow up of VL results (TAT reduced to <10 days) Case workers expedite VL result notification to caregiver and filing Multi-stakeholder case conferencing conducted for unsuppressed VLs

·Community-based VL sample collection integrated in quantification and forecast processes ·Providers sensitized to flag VL testing during routine clinical reviews

Results:

- Since FY21, the ECAP program facilitated 3,371 viral load tests
- VLC for OVC living with HIV in the ECAP program increased from 55% to 90%

Adolescent-friendly Health Centers (AFHCs) promote improved viral suppression for ALHIV through comprehensive service delivery in India




- 1. Case profiling
- 2. Categorization and prioritization
- 3. Intensive care services
- 4. ART adherence barrier assessment
- 5. Developing individualized ART adherence barrier interventional plan
- 6. Developing assisted action plan










- 7. Skill building and cultural activities
- 8. 104 ALHIV on MMD, 15 ALHIV on CARG, 181 eligible for FCA, 101 completed FCA



Summary of Key Activities for C/ALHIV



Pediatric Maternal Clinical Branch Technical PoCs

Technical Area	POC	Email
PBFW & Peds Virologic Suppression and HIVDR	Nicole Buono (PAC) & Alex Vrazo (MlhC)	nbuono@usaid.gov; avrazo@usaid.gov
Adolescent Care and Treatment	Tishina Okegbe & Kate Plourde	tokegbe@usaid.gov
Peds MMD	Lauren Bailey	lbailey@usaid.gov
EMTCT & Comprehensive Care for HEI	Alex Vrazo	avrazo@usaid.gov
Peds/OVC TU	Megan Gleason	mgleason@usaid.gov
PBFW & Peds Retention/DSD	Ola Faturiyele	ifaturiyele@usaid.gov
PBFW & Peds HIV Case Finding/HIVST	Meena Srivastava Ronnie Lovich	msrivastava@usaid.gov rlovich@usaid.gov
Peds ART	Anouk Amzel	aamzel@usaid.gov



Presenter: Kristina Bishop Senior HIV Testing Services Advisor, GH/OHA





38

REMINDERS- changes to current COP22 guidance

- 1 2 3
 - Positivity targets for OtherPITC have been removed from COP22 guidance
 - ALL index metric minimum standards (except 100 percent offer) have been removed from COP22 guidance
 - Programs should determine for themselves how to target testing for their own epidemics

Slide 39	
1	this is min positivity targets - but positivity targets will still be derived in the DATA PACK Vincent Wong, 11/12/2022
2	added it's the min stds that have been removed. can we reference the table and page from COP22 guidance Vincent Wong, 11/12/2022
3	is this trueand it means Agencies correct? (vs pgms)
	also include an HIVST bullet on multiple kits being available and expanded use. Vincent Wong, 11/12/2022


HTS Should Be Status Neutral

From the PEPFAR Strategic Direction 2022

FOCUS AREA 4: HIV TESTING SERVICES


Support approaches for status neutral HIV testing services, including testing for HIV prevention (e.g., in context for PrEP interventions), access to HIV self-testing, and strategic case finding to achieve the first 95, while investing in new approaches such as multiplex testing and re-engagement strategies.

- "The status-neutral approach begins with an HIV test which is followed by active engagement of that person regardless of their HIV status. Those who tested HIV-positive are engaged in treatment right away while those who tested HIV-negative are also immediately engaged in PrEP or postexposure prophylaxis (PEP), visualizing that the clinical, programmatic, or social "HIV" divide is nonexistent."
- "Both HIV-positive and HIV-negative individuals end at a common final stage of being continuously engaged in clinical care with negligible risk of either transmitting or acquiring HIV."



Testing Within Prevention as a Part of Status Neutral Testing

Status neutral testing has a broader scope than just testing for case finding and actively supports linkage to and engagement in prevention programs.




TxAP Expected to be Standard. PITC Already Widely Optimized

Estimated Number of Adult PLHIV - Number of Adult PLHIV on ART

Treatment Adjusted Prevalence =

Treatment adjusted prevalence estimates the expected positivity in a testing program by accounting for both national HIV prevalence and ART coverage. The treatment adjusted prevalence is calculated to account for individuals with HIV who are a) diagnosed, b) previously diagnosed and treatment naive, or c) previously diagnosed with an interruption in treatment. To account for second 95 achievements, individuals who are on ART are excluded from the calculation.



Total Adult Population - Number of Adult PLHIV on ART

Decreased Emphasis on Use of Risk Screening Tools

Section 6.3.1.7 on Using HIV Risk Screening Tools in PITC Settings (p. 322-324) is expected to be deleted and replaced with the following wording:

An HIV risk screening tool is a set of questions (behavioral, demographic, symptom-based, etc.) used to identify individuals who need HIV testing. In accordance with WHO guidance, risk screening tools should be validated for the program's setting, and should have a screen-in approach.

Due to 1) the lack of screen-in tools that are validated for appropriate sensitivity, and 2) the increased availability of highly sensitive and more affordable HIV self-test (HIVST) assays, programs are encouraged to optimize the use of HIVST within PITC. For populations with very low prevalence and low testing coverage (e.g., children), validated, screen-in risk screening may be considered to help increase testing coverage among these individuals




Slide deck from WHO Webinar on the use of risk assessment tools

	Carrent H90/AIDS Reports (2022) 19:154-165. https://doi.org/10.1007/s11904-022-00601-5	
	THE SCIENCE OF PREVENTION IR HEFFRON AND K NO	SURE, SECTION EDITORS)
	Risk-Based Screening Tools to Optimise a Systematic Review	HIV Testing Services:
	J. J. Ong ^{1,2,3} · K. Coulthard ² · C. Quinn ⁴ · M. J. Tang ¹ · T. Hu	aynh ¹ · M. S. Jamil ⁴ · R. Baggaley ⁴ · C. Johnson ⁴
	Accepted: 31 January 2022 / Published online: 11 February 2022 6 The Authoritic 2022	
	global priority. We reviewed the use of viak based tools, are tested (screen in) or excluded people from testing (screen out Recent Mediags Recent studies suggest that there may be valu- ing those who need to be tested). However, there has not been Sommary We detertifed Rel28 (scations), and 30 (here) includ- high-iscone (SH3) and how HW (<sh3) constru-<br="" prevalence="">high-test performance tools related to dointing the MM with as</sh3)>	e in risk-based tools to improve testing efficiency (i.e. identify- nary systematic reviews to synthesize these studies. (e) The risk-based tools identified were most commonly from (2)(5). The majority were for "accreasing in" (20%), with the state BIV. Screening in tools may be helpful in settings where it is in secold for screening out tools, where there is a trade-off
	Introduction	As nations strive to meet United Nation's (UN) 95-95-95
Systematic Poviow	Globally, an coimated 6.0 million people itving with HTV (PLRV) remain summer of their status, appendiumly HT of the cost population of PLRVITV [11]. This pap in historhold of HTV status is a significant public heads poolses, whereby these living with HTV who are not listed to appropriate treatment and care hore higher HTV-related mortally and morthful [2]. Finding effective and ficiant ways to close this tenting gap is an argent global priority.	toting and treatment targets—with the first target referring to having 95% of WLRV dapased ad answ of their stars by 2025 [D]—efforts to track the remaining undiaghosed individuals is to indeging and costly, scontiers successfully control the HUV epidemic, HUV positivity (or yield) may decline in parallel with accesses in toring and treatment coverage, thereby increasing the cost per person dag- mosed. Construst also need to make studied and maldel income construction in large of HUV familiag an increased maldel income construction and maldel income constructions and income construction
Systematic Review	This article is part of the Topical Collection on The Science of Prevention	services as a result of the COVID-19 pandemic [4]. Strategic use of HIV testing services (HTS) approaches, including partner services [5], community-based testing [6++], and
on the use of risk	Si J.J. Org Jason org@tsonash.nls; Jason Org@ldem.ac.uk	HIV self-testing [7, 8], focused on geographic areas, and populations with the greatest HIV burden and unmet testing need have proven effective and efficient in reaching people
	¹ Central Classical School, Monash University, Melbourne, Australia	with undiagnosed HIV infection. Another strategy to consider is using risk-based screen-
<u>based screening</u>	¹ McDourne Sonial Health Contre, The Albed Hospital, Melbourne, Australia ² Department of Clinical Research, London School of Hyziene	ing tools in HIV testing services. Risk-based screening tools typically use a set of criteria to either identify high-risk indi- viduals for HIV testing who would not otherwise be offered
tools	and Tropical Medicine, London, UK Global HIV, Hepatitis and STIs Programmes, World Meabh Organization, Geneva, Switzerland	a test (screen in) or exclude low-risk people from a rou- tine offer of the test (screen out). Tools may be electronic
	D Springer	


HIVST Should Continue to be Scaled. Decrease Data Push.

- HIVST means an individual performs a test on themselves in private or under observation of a professional if they so desire. It should be voluntary and not forced or coerced.
 People who use a self-test should not be forced or coerced to disclose the result of that test to anyone, and should only do so voluntarily.
 - Data shows that HIVST linkage rates are comparable to conventional testing



HIVST Should Continue to be Scaled. Decrease Data Push. (pt 2)

- HIVST can increase testing coverage w/ out HRH burden of conventional testing
- HIVST has uses for both case-finding (e.g. increased coverage in high burden facility settings, replace screening tools in OPDs, community outreach for KPs & high burden areas, secondary distribution through index & SNS) and prevention (e.g. PrEP initiation & continuation, secondary distribution to partners, AGYW distribution, SRH distribution)
- Virtual platforms w/ private sector distribution should be scaled (eg pharmacies & retail vendors)
- Advocacy for regionalization of HIVST storage and/or manufacturing



HIVST Use Expanded for PrEP - But Not For Initiation

Main points from the recent WHO guidance:

- HIVST can complement existing HIV testing strategies for PrEP to support differentiated service delivery approaches for oral PrEP and the DVR to reduce clinic visits, and it may increase PrEP use and frequency of HIV testing.
- HIVST provides an additional testing choice to PrEP users when starting, restarting or continuing PrEP, which may be preferred for convenience, privacy and self-managed care.

PEPFAR supports the revised WHO guidelines on the use of HIV selftesting to facilitate easier access to and use of PrEP for prevention clients, **including PrEP continuation**, **re-initiation**, **and effective use**

Note that unlike the WHO guidance, PEPFAR is NOT recommending HIVST use for PrEP initiation

Differentiated and

July 2022 WHO Guidance

Key Populations

Presenter: Patrick Hazelton Sr. Key Populations Technical Advisor, GH/OHA





47

KP Local Partner performance rivals KP Central Mechanisms!

		Local	Partner KP Mecha	nisms	Ce	entral KP Mechanis	ms
Share of Results		QI-Q3 Results	Targets	Target Achievement	QI-Q3 Results	Targets	Target Achievement
	KP_PREV (Q2)	564,906	537,227	105%	309,344	365,997	85%
•	PrEP_NEW	94,534	63,532	149%	43,013	48,205	89%
	HTS_SELF	131,588	192,122	68%	86,189	59,966	144%
	HTS_TST	666,052	379,782	175%	321,968	226,188	142%
	HTS_TST_POS	35,100	31,337	112%	21,023	20,625	102%
	TX_NEW	30,598	26,707	115%	17,754	12,685	140%
	TX_CURR	128,289	122,603	105%	87,606	53,094	165%
	TX_PVLS (D)*	87,282	82,763	105%	26,973	50,591	53%
	TX_PVLS (N)*	84,421	78,515	108%	25,857	48,086	54%

FY22 KP Target Achievement Comparison of Local Parter and Central KP Mechanisms, USAID

*5 central mechanisms are unable to report KP disaggregated TX_PVLS results which decreases KP TX_PVLS achievement. Total achievement is somewhat higher than shown here for Central KP mechanisms, but results still fall below targets. **Note:** This is not a comprehensive view of USAID KP performance. It intentionally excludes bilateral, international partners implementing KP programs.

Vast majority of global HIV burden lies with Key Populations


- 70% of new HIV infections in 2021 were among key populations and their sexual partners
 KPs account for less than 5% of the global population
- What does this mean for the focus of PEPFAR programs in the future?

Relative risk of HIV acquisition, global (2021)



Every region has a substantial population of vulnerable KPs

- In Sub-Saharan Africa KPs and their partners represent 51% of those infected while in the rest of the world they represent 94%
- How is PEPFAR addressing the unique needs of KPs in <u>all</u> regions and countries?



Key Populations are central to equity in the HIV response

There is a **public health imperative** to differentiate services

- Missed 2020 targets
- Equity lens includes renewed focus on structural issues, human rights
- Epi lens can focus on heterogeneity of risk + prevention impact (coverage to halt transmission over time)

UNAIDS, WHO, and PEPFAR underscore the **importance of vulnerable populations** in global strategies and guidance

- 95–95–95 testing and treatment targets are achieved within all subpopulations, age groups and geographic settings, including CLHIV
- 10-10-10s

END INEQUALITIES. END AIDS. GLOBAL AIDS STRATEGY 2021-2026

• PEPFAR Pillar 1: Health Equity "Know and close your gaps" by scaling up evidence-based programs with differentiated services

- DSD scaled nationally, institutionalized within sustainable health systems
- Robust commitment to primary HIV prevention (invest in understanding onward transmission)
- Integrate services
- Embrace innovation

Key Populations are central to equity in the HIV response



Integrate services for HIV, sexual and reproductive health, family planning, NCDs, and emerging infectious disease threats to advance health equity and sustainability.



DSD FOR ALL SERVICES

Institutionalize differentiated approaches in the context of integrated services, for all services and all populations, to close gaps and strengthen primary care.



Prioritize and allocate resources to eliminate ongoing stigma and discrimination as the basis of human rights-based programming.



FOCUS ON INDIVIDUAL AND GAPS

Focus on individual needs and gaps, tailoring interventions and linking activities across sites, systems, and individuals to improve prevention and retention in care.



COMMUNITY-LED SERVICES + CLM


Increase systems sustainability by reaching into community sites and focusing on populations' unmet needs, not just more funding for each siloed population.

Structural Interventions are essential to KP Programming


- A Fostering Enabling Policy Environments:
- Supporting decriminalization/ anti-discrimination advocacy
- Engaging law enforcement and legal services
- Providing minimum set of human rights policies

D: Meeting KP community needs

- Human Rights (HR) Violation
 Response & Reporting System
- KP-specific health services linked to HIV outcome
- Social protections linked to services
- KP socio-economic empowerment



What's new in WHO's consolidated KP guidelines



World Health

Organization

Why we must **prioritize** key populations in the response to HIV, viral hepatitis and STIs

What's new in WHO's consolidated KP guidelines

Prioritizing interventions

World Health Organization

Essential for impact: enabling interventions

interventions recommended to address structural barriers to health services access for key populations.

Essential for impact: health interventions

interventions which have a demonstrated direct impact on HIV, viral hepatitis and STIs in key populations.

Essential for broader health

health sector interventions to which access for key populations should be ensured, but which do not have direct impact on HIV, viral hepatitis or STIs.

Supportive

other interventions which support the delivery of health sector interventions, such as creating demand, providing information and education.

ESSENTIAL IN ALL SETTINGS

What's new in WHO consolidated KP guidelines

Behavioural interventions

and STIs, policy-makers and providers should be aware that
New good practice counselling behavioural interventions that aim to change behaviours
statement to reduce risks associated with these infections for key populations
have not been shown to have an effect on HIV, viral hepatitis and
STI incidence nor on risk behaviour such as condom use and needle
sharing. Counselling and information-sharing, not aimed at changing
behaviours, can be a key component of engagement with key
populations, and when provided it should be in a non-judgmental
manner, alongside other prevention interventions and with involvement of peers.

World Health Organization

Remarks:

- Behavioural interventions, counselling, demand creation, information and education can all support the recommended interventions. In the development of this guideline, we did not find evidence for the effectiveness of counselling behavioural interventions that aim to change risk behaviours;
- While we did not review evidence related to other types of behavioural or supportive interventions, information and education support key ٠ populations to understand their health, health risks, available services and legal rights;
- Counselling interventions which promote abstinence from drug use, rehabilitation or cessation of sex work or drug use, or a so-called cure for . homosexuality or gender incongruence (for example, so-called conversion therapy)* are not recommended, and create barriers to key population service access.

Discussion and Questions





57

Thank you!





58